RATIONALE: The management of chronic thromboembolic pulmonary hypertension (CTEPH) has changed over recent years with the growth of pulmonary endarterectomy surgery and the availability of disease-modifying therapies. OBJECTIVES: To investigate the prognosis of CTEPH in a national setting during recent years. METHODS: All incident cases diagnosed in one of the five pulmonary hypertension centers in the United Kingdom between January 2001 and June 2006 were identified prospectively. Information regarding baseline characteristics, treatment, and follow-up was subsequently collected from hospital records. MEASUREMENTS AND MAIN RESULTS: A total of 469 patients received a diagnosis, of whom 148 (32%) had distal, nonsurgical disease. One- and three-year survival from diagnosis was 82 and 70% for patients with nonsurgical disease and 88 and 76% for those treated surgically (P = 0.023). Initial functional improvement in patients with nonsurgical disease was noted but did not persist at 2 years. Significant functional and hemodynamic improvements were seen in surgically treated patients with an increase in six-minute-walk distance of 105 m (P < 0.001) at 3 months. Five-year survival from surgery in the 35% of patients who survived to 3 months but had persistent pulmonary hypertension was 94%. CONCLUSIONS: The prognosis in nonsurgical disease has improved. We have confirmed the previously described good outcome in surgically treated disease. However, we have also demonstrated that the long-term prognosis for patients who have persistent pulmonary hypertension at 3 months after surgery is good. The observed improvements in outcome during the modern treatment era reinforce the importance of identifying patients with this increasingly treatable condition.
RATIONALE: The management of chronic thromboembolic pulmonary hypertension (CTEPH) has changed over recent years with the growth of pulmonary endarterectomy surgery and the availability of disease-modifying therapies. OBJECTIVES: To investigate the prognosis of CTEPH in a national setting during recent years. METHODS: All incident cases diagnosed in one of the five pulmonary hypertension centers in the United Kingdom between January 2001 and June 2006 were identified prospectively. Information regarding baseline characteristics, treatment, and follow-up was subsequently collected from hospital records. MEASUREMENTS AND MAIN RESULTS: A total of 469 patients received a diagnosis, of whom 148 (32%) had distal, nonsurgical disease. One- and three-year survival from diagnosis was 82 and 70% for patients with nonsurgical disease and 88 and 76% for those treated surgically (P = 0.023). Initial functional improvement in patients with nonsurgical disease was noted but did not persist at 2 years. Significant functional and hemodynamic improvements were seen in surgically treated patients with an increase in six-minute-walk distance of 105 m (P < 0.001) at 3 months. Five-year survival from surgery in the 35% of patients who survived to 3 months but had persistent pulmonary hypertension was 94%. CONCLUSIONS: The prognosis in nonsurgical disease has improved. We have confirmed the previously described good outcome in surgically treated disease. However, we have also demonstrated that the long-term prognosis for patients who have persistent pulmonary hypertension at 3 months after surgery is good. The observed improvements in outcome during the modern treatment era reinforce the importance of identifying patients with this increasingly treatable condition.
Authors: John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba Journal: Circulation Date: 2016-04-06 Impact factor: 29.690
Authors: Bastiaan E Schölzel; Martijn C Post; Alexander van de Bruaene; Steven Dymarkowski; Wim Wuyts; Bart Meyns; Werner Budts; Marion Delcroix Journal: Int J Cardiovasc Imaging Date: 2014-08-22 Impact factor: 2.357
Authors: Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba Journal: J Heart Lung Transplant Date: 2010-03-15 Impact factor: 10.247
Authors: Nadine Al-Naamani; Gaudalupe Espitia H; Hugo Velazquez-Moreno; Benjamin Macuil-Chazaro; Arturo Serrano-Lopez; Ricardo S Vega-Barrientos; Nicholas S Hill; Ioana R Preston Journal: Lung Date: 2016-01-09 Impact factor: 2.584